Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.28 +0.37 (+1.28%)
Official Closing Price Updated: 7:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic 
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news. 
Via Investor's Business Daily
This Is What Whales Are Betting On Pfizer
Via Benzinga
Is Pfizer Stock a Buy Now?
Pfizer shares have fallen by double digits this year. 
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate... 
Via Talk Markets
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
For growth investors, it may be time to sell this pharma stock for tax-loss harvesting purposes. 
Via The Motley Fool
Why Pfizer Stock Is Sinking Today
The big drugmaker delivered bad news for its top pipeline program. 
Via The Motley Fool
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
How To Make $500 A Month With Pfizer Stock
Pfizer Inc. (NYSE: PFE) shares closed higher on Wednesday. 
Via Benzinga
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
5 Top Stocks to Buy Before 2024
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
Kicking off the new month, Wall Street continued its strong November momentum, with major U.S. stocks rallying on Friday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Hub Cyber Security (HUBC) Stock Up 30% Today?
Hub Cyber Security stock is rising higher on Friday as HUBC investors react to an expanded partnership with Blackswan Technologies. 
Via InvestorPlace
Why Is Altimmune (ALT) Stock Up 43% Today?
Altimmune stock is rising higher on Friday with heavy trading of ALT shares after posting positive results form a clinical trial. 
Via InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
Pfizer layoffs are on the way for workers at the company's Groton, Conn. facility as it seeks to reduce costs by cutting jobs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely- 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell. 
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug. 
Via Talk Markets
Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide  
Via Benzinga
This Twice Daily Weight Loss Drug Has Adverse Side Effects And Pfizer Wants To Discontinue It
Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in... 
Via Benzinga
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
From Pfizer Inc.
Via Business Wire
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless. 
Via InvestorPlace
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... 
Via SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Loser Stocks: Buy More, Hold Or Sell?
Many investors bought during the exciting go-go days of the pandemic, as stocks surged to new all-time highs. But many stocks, especially the technology growth stocks, plunged in 2022. 
Via Talk Markets
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks. 
Via InvestorPlace
Companies That Grow Through Acquisitions: Pros And Cons
We hit one of dividend growth investors’ favorite business model types: growth through acquisitions. While it often rhymes with dividend growth, there are pros and cons to consider. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.